An increased expression level of EZH2 inhibits the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase (cGAS) activity, dampening the cGAS-stimulator of interferon genes (STING)-interferon-β (IFNβ) pathway and resulting in lower immunotherapy sensitivity among CRC patients [49]. The gene discussed is EZH2; the disease is colorectal carcinoma.